Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SLAMF7 BATs |
Synonyms | |
Therapy Description |
SLAMF7 BATs are activated T-cells armed with bispecific antibodies that target both SLAMF7 (also known as CS1) and CD3, which release cytokines upon target cell binding and may lead to cytotoxicity against tumor cells (PMID: 32432032). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SLAMF7 BATs | CS-1 BAT|Anti-CS1 x Anti-CD3 Bispecific Antibody | SLAMF7 BATs are activated T-cells armed with bispecific antibodies that target both SLAMF7 (also known as CS1) and CD3, which release cytokines upon target cell binding and may lead to cytotoxicity against tumor cells (PMID: 32432032). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04864522 | Phase I | SLAMF7 BATs | Pilot Study of SLAMF7 BATs/CS-1 BATs in Relapsed/Refractory Multiple Myeloma (MM BATs) | Withdrawn | USA | 0 |